| 摘要 |
Disclosed are compound represented by the general formula I which modulate the activity of MCH receptors and are notable for an antagonism of the MCH1R, in which the meanings are: R1, R1', R1'', R1''' independently of one another are H, F, Cl, Br, I, OH, CF3, NO2, CN, OCF3, O-alkyl, O-alkoxy-alkyl, S-alkyl, alkyl, alkenyl, cycloalkyl, O-cycloalkyl, cycloalkenyl, alkynyl, alkylene-aryl, O-alkylenearyl, S-aryl, N(R3)(R4), SO2-CH3, COOH, COO-alkyl, CON(R5)(R6), N(R7)CO(R8), N(R9)SO2(R10), CO(R11) or (C(R12)(R13))x-O(R14); Y is C(R27)(R27')C(R28)(R28') or C(R29)=C(R29'); X is S, O or C(R30)=C(R30'); A is a bond or a linker having 1 to 8 members; B is H, N(R35)(R36), hydroxy-alkyl, alkyl, alkoxy-alkyl, alkenyl, alkynyl or a 3 to 10-membered mono-, bi-, tri- or spirocyclic ring which may comprise 0 to 4 heteroatoms selected from the group of oxygen, nitrogen and sulphur, where the ring system may additionally be substituted; Q is a mono-, bi-, tri- or spirocyclic saturated or partly unsaturated ring structure having one nitrogen atom and 0-3 further heteroatoms; and wherein the remaining substituents are as defined herein. Also disclosed is the use of a compound as defined above in the manufacture of a medicament for the treatment and/or prevention of disorders of fatty acid metabolism, glucose utilization disorders, disorders in which insulin resistance is involved, diabetes mellitus and the squelae associated therewith, dyslipidemias and the squelae thereof and conditions associated with the metabolic syndrome. |
